CADTH Canadian Drug Expert Review Committee final recommendation: Riociguat (Adempas - Bayer HealthCare Inc.) indication: pulmonary arterial hypertension
The CADTH Canadian Drug Expert Review Committee (CDEC) recommends that riociguat be listed for the treatment of pulmonary arterial hypertension
Corporate Authors: | , |
---|---|
Format: | eBook |
Language: | English |
Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2015, 2015
|
Series: | CADTH common drug review
|
Subjects: | |
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Summary: | The CADTH Canadian Drug Expert Review Committee (CDEC) recommends that riociguat be listed for the treatment of pulmonary arterial hypertension |
---|---|
Item Description: | "Notice of Final Recommendation - December 17, 2015." |
Physical Description: | 1 PDF file (6 pages) |